However, excessive PGC-1α alters mitochondrial properties and induces podocyte proliferation and dedifferentiation, causing collapsing glomerulopathy.534 Therefore, controlling the exact levels of PGC-1α and establishing the optimal therapeutic window for PGC‐1α activation is significant to achieve clinical benefits. Here, PPARGC1A is linked to glomerular disorder.